Skip to content

Welcome to Discover Pharma! Today is : October 23, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Biotech & Pharma Business

  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    MaaT Pharma to advance Phase 3 trial after EMA rejects MaaT013 application

    MaaT Pharma plans to advance a global Phase 3 trial [...]

    September 18, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Genomics and sequencing,Manufacturing & Supply Chain,Research & Development

    Saudi Arabia announces biotech deals and research partnerships worth SAR 5.5BN

    Saudi Arabia has announced more than SAR 5 billion in [...]

    September 18, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Big Picture Bio launches with £2.2M to design cancer drug combinations

    Big Picture Bio has launched with £2.2 million in funding [...]

    September 18, 2026
  • Advanced Therapies,Biotech & Pharma Business,Research & Development

    Oncodesign Services and Nexus BioQuest form preclinical research partnership

    Oncodesign Services and Nexus BioQuest have formed a preclinical research [...]

    September 17, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Pharmaceuticals and therapeutics,Research & Development

    Calibre secures CQC registration for nationwide AI health service

    Calibre Health Labs has secured CQC registration, allowing its doctors [...]

    September 17, 2026
  • Advanced Therapies,Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    NIH funds expanded access programme for Neurizon’s ALS therapy

    A US National Institutes of Health grant will fund an [...]

    September 16, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Sapience Therapeutics gets FDA clearance for ST316 FAP study

    The FDA has cleared Sapience Therapeutics to begin clinical development [...]

    September 16, 2026
  • Biotech & Pharma Business,Digital & Data,Research & Development

    Lifebit awarded three-year NIHR BioResource research environment contract

    Lifebit has been awarded a three-year contract by the University [...]

    September 16, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics

    Resolution Therapeutics partners with Blood Centers of America for RTX001 programme

    Resolution Therapeutics has partnered with Blood Centers of America to [...]

    September 16, 2026
  • Advanced Therapies,Biotech & Pharma Business,Pharmaceuticals and therapeutics,Research & Development

    Eleva separates biologics platform from Factor H therapy

    Eleva is separating its moss-based biologics platform from its clinical-stage [...]

    September 15, 2026
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Carterra and AstraZeneca target AI-driven drug discovery
    Categories: Biotech & Pharma Business, Digital & Data, Drug Discovery & Development, Research & Development
  • Biopharma dealmaking outlook improves despite investor caution
    Categories: Biotech & Pharma Business, Research & Development
  • SurVaxM improves survival in Phase 2b glioblastoma trial
    Categories: Central Nervous System, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top